Chromocell Therapeutics Corp
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
PTHS$9.37+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
| March 31, 2024 (Unaudited) | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $3,770,229 | $96,391 |
| Prepaid expenses | 220,930 | — |
| Due from Chromocell Corporation | 40,400 | — |
| TOTAL CURRENT ASSETS | 4,031,559 | 96,391 |
| TOTAL ASSETS | $4,031,559 | $96,391 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $2,407,515 | $4,620,925 |
| Accrued compensation | 493,924 | 645,947 |
| Bridge loan, net of debt discount | — | 316,324 |
| Loan payable, net of debt discount | — | 202,279 |
| Loan payable - related party, net of debt discount | — | 750,082 |
| Due to Chromocell Corporation | — | 5,386 |
| TOTAL CURRENT LIABILITIES | 2,901,439 | 6,540,943 |
| TOTAL LIABILITIES | 2,901,439 | 6,540,943 |
| COMMITMENTS AND CONTINGENCIES | ||
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Preferred stock Series A, $0.0001 par value, 700,000 shares authorized, 0 and 600,000 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | — | 60 |
| Preferred stock Series C, $0.0001 par value, 5,000 shares authorized, 2,600 and 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized, 5,766,704 and 3,914,338 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 578 | 391 |
| Additional paid in capital | 17,211,521 | 7,074,646 |
| Accumulated deficit | (16,081,979) | (13,519,649) |
| TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | 1,130,120 | (6,444,552) |
| TOTAL LIABILITIES, AND STOCKHOLDERS’ EQUITY (DEFICIT) | $4,031,559 | $96,391 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.